Solution for injection - 0.5 mg / 1 ml

Prozerine contains the active substance neostigmine metilsulfate, which inhibits cholinesterase activity and thus prolongs and intensifies the physiological actions of acetylcholine. It probably also has direct effects on skeletal muscle fibres. The anticholinesterase actions of neostigmine are reversible.

After parenteral doses, Prozerine is excreted in the urine both as unchanged drug and metabolites. It undergoes hydrolysis by cholinesterases and is also metabolised in the liver.

Prozerine is indicated:

• in the treatment of Myasthenia gravis;
• as antidote to the non-depolarising neuromuscular blockers;
• in the treatment of paralytic ileus and postoperative urinary retention.